Three hours after injection, free FAM-siRNA displayed faint fluorescence intensity at the tumor site, suggesting the instability and rapid clearance of naked siRNA in vivo, as shown in Figure 6A. By contrast, siTGF-β1@ILP containing the same amount of FAM-siRNA revealed distinct fluorescence at the tumor site, confirming stability in vivo and the successful delivery of siRNA to the tumor region via siTGF-β1@ILP, which was attributed to the active targeting and binding ability of CTX to EGFR. This evidence concerns the gene EGFR and neoplasm.